Clinical Trials of Coronary Stents in India: An Update
DOI:
https://doi.org/10.17140/HROJ-3-128Keywords:
Drug eluting stents; Coronary artery disease, National Interventional Council (NIC).Abstract
The Coronary Artery Disease (CAD) burden increased in Indian population and even it is increasing
in young Indians. There are more ways to treat these patients and coronary stents are
one of the option for them. In the present short communication I am presenting the number of
trials, number of patients involved and the limitation of the trials conducted in Indian coronary
artery disease patients.
References
Press Trust of India. Angioplasties performed in India rise by 42 pc in 2015: NIC. Web site. http://www.business-standard. com/article/pti-stories/angioplasties-performed-in-india-rise-by-42-pc-in-2015-nic-116041600486_1.html. Accessed June 8, Heart Res Open J 2016
3V NEIL. Sirolimus Drug Eluting Stent System. Web site. http://www.s3vvascular.com. Accessed June 8, 2016
National Institute of Medical Statistics. Clinical Trials Reg-istry-India. Web site. http://ctri.nic.in/Clinicaltrials/advsearch. php. Accessed June 8, 2016.
Seth A, Patel TM, Stuteville M, et al. Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients. Indian Heart J. 2014; 66(3): 302-308. doi: 10.1016/j.ihj.2014.03.007
Rissam HS, Kishore S, Trehan N. Coronary artery disease in young Indians – The missing link. Indian Academy of Clinical Medicine. 2001; 2(3). Web site. http://medind.nic.in/jac/t01/i3/ jact01i3p128.pdf. Accessed June 8, 2016
Krishnan MN. Coronary heart disease and risk factors in In-dia-On the brink of an epidemic? Indian Heart J. 2012; 64(4): 364-367. doi: 10.1016/j.ihj.2012.07.001
Sekhri T, Kanwar RS, Wilfred R, et al. Prevalence of risk factors for coronary artery disease in an urban Indian population. BMJ Open. 2014; 4: e005346. doi: 10.1136/bmjopen-2014-005346
Krishnan MN, Zachariah G, Venugopal K, et al. Prevalence of coronary artery disease and its risk factors in Kerala, South In-dia: A community-based cross-sectional study. BMC Cardiovasc Disord. 2016; 16: 12. doi: 10.1186/s12872-016-0189-3
Chandra P, Kumar T. A prospective, multicenter, post market-ing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India. Indian Heart J. 2014; 66: 682-685. doi: 10.1016/j.ihj.2014.10.422
Patted SV, Halkatti P, Modi R. Effect of stent length on clinical outcome in patients with coronary artery disease. Indian Journal of Science and Technology. 2015; 8(4): 329-336. doi: 10.17485/ijst/2015/v8i4/62284
C.G. Bahuleyan , V.V. Krishna Kumar , ShifasBabu. Prospec-tive study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions. In-dian Heart J. 2015; 67: 233-238. Web site. http://www.pubpdf. com/pub/26138180/Prospective-study-to-evaluate-safety-and-efficacy-of-Zotarolimus-Eluting-Stent-PSEZES-in-patients-wi. Accessed June 8, 2016
Sastry BK, Kumar N, Menon R, et al. Real world experience with an indigenously manufactured stent Cobal C-A retrospec-tive study. Indian Heart J. 2014; 66: 525-529. doi: 10.1016/j. ihj.2014.08.015
Mehta AB, Chandra P, Dalal J, et al. One-year clinical out-comes of BioMatrix-Biolimus A9 eluting stent: The e-BioMatrix multicenter post marketing surveillance registry in India. Indian Heart J. 2013; 65: 593-599. doi: 10.1016/j.ihj.2013.08.031
Seth A, Hiremath S, Dani S, et al. Clinical outcomes with Biolimus (A9) eluting stent, ‘BioMatrix’ in diabetic patients -Interim results from multicenter post market surveillance regis-try in India. Indian Heart J. 2013; 65: 586-592. doi: 10.1016/j. ihj.2013.08.030
Abhyankar AD, Thakkar AS. In vivo assessment of stent recoil of biodegradable polymer-coated cobalt-chromium siro-limus-eluting coronary stent system. Indian Heart J. 2012; 64: 541-546. doi: 10.1016/j.ihj.2012.07.005
Seth A, Chandra P, Chouhan NS, Thakkar AS. A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J. 2012; 64: 547-552. doi: 10.1016/j.ihj.2012.07.011
Legutko J, Zasada W, Kałuża GL, et al. A clinical evaluation of the ProNOVA XR polymer free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). Indian Heart J. 2013; 65: 388-394. doi: 10.1016/j.ihj.2013.06.026
Rothman M. Resolute zotarolimus eluting stent for treatment of long coronary lesions. Indian Heart J. 2015; 67: 194-195. doi: 10.1016/j.ihj.2015.05.007
Stone GW, Abizaid A, Silber S, et al. Prospective, random-ized, multicenter evaluation of a polyethylene terephthalate mi-cronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: The MASTER trial. J Am Coll Cardiol. 2012; 60: 1975-1984. doi: 10.1016/j.jacc.2012.09.004
Hiremath S, Chandra P, Desai D, et al. A prospective, multi-centric, observational registry to evaluate performance of Ex-cel™ DES in ‘Real World, All Comers’ patient population. Indian Heart J. 2014; 66: 691-695. doi: 10.1016/j.ihj.2014.12.009
Goyal BK, Kalmath BC, Kawar R, Sharma A, Khemnar B, Rangnekar H. Experience with BioMatrix BES and other DES in all-comers setting: A retrospective overview. Indian Heart J. 2013; 65: 678-682. doi: 10.1016/j.ihj.2013.10.014
Kaul U, Abhaichand R, Patel T, et al. A randomized compari-son of taxus element vs. xience prime in Indian patients with dia-betes mellitus (TUXEDO India). Indian Heart J. 2014; 66(Suppl 2): S104. doi: 10.1016/j.ihj.2014.10.289 Heart Res Open J
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.